Histological prognostic factors in children with Henoch Schönlein Purpura nephritis

Jean-Daniel Delbet^{1,2}, Guillaume Geslain¹, Martin Auger¹, Julien Hogan^{3,4}, Rémi Salomon⁵, Michel Peuchmaur³, Georges Deschênes^{3,4}, David Buob⁶, Cyrielle Parmentier¹, Tim Ulinski^{1,2},

¹Pediatric Nephrology, Armand Trousseau Hospital, APHP, Paris, France

²University Pierre and Marie Curie, Paris 6, Paris, France

³Pediatric Nephrology, Robert Debré Hospital, APHP, Paris, France

⁴University Paris Diderot, Paris 7, Paris, France

⁵Pediatric Nephrology, Necker Enfants Malades, APHP, Paris, France

⁶Pathology Department, Tenon Hospital, APHP, Paris, France

Corresponding author

Jean-Daniel Delbet, MD

Department of Pediatric Nephrology,

Armand Trousseau Hospital

26 Avenue du Docteur Arnold Netter, 75012 Paris, France

Tel: +33-144736662; Fax: +33-144736663

Email: jean-daniel.delbet@.aphp.fr

Keywords: Henoch-Schonlein purpura nephritis, IgA vasculitis with nephritis, renal outcomes, pediatric, histological prognostic factors

Abstract

Introduction. The management of IgA vasculitis with nephritis (IgAVN) remains controversial because of the difficulty to identify prognostic factors. This study reports the prognosis of children with IgAVN in relation to histological parameters.

Methods. All children with IgAVN diagnosed between 2000 and 2015 in three pediatric nephrology centers were included. The following histological parameters were analyzed: mesangial proliferation (MP), endocapillary proliferation (EP), crescents, active or chronic tubular and interstitial lesions (T1a lesions / T1c lesions), and segmental glomerulosclerosis (GS). Clinical and biological data were collected at the time of renal biopsy. The primary endpoint was IgAVN remission defined as a proteinuria <200 mg/L without renal failure.

Results. 159 children were included with a median age of 7.6 years. Acute glomerular or TI lesions including MP, EP, crescents, and T1a lesions were observed, respectively, in 81%, 86%, 49%, and 21% of patients. Chronic glomerular lesions including GS and T1c lesions were observed in 6 and 7% of patients. Median initial proteinuria was 330 mg/mmol, albuminemia 32 g/l, and eGFR 110 ml/min/1.73m². 112 (70%) patients were in remission at the end of a median follow up of 37.4 months. Chronic lesions were significantly associated with the absence of remission in multivariate analysis, whereas EP, crescents and T1a were not associated with a poor prognosis.

Conclusion. 30% of children with IgAVN present a persistent renal disease at the end of a 3-year follow-up. Chronic histological lesions, but not EP or crescents are associated with a bad prognosis and must be evaluated in IgAVN histological classification.

Introduction

IgA vasculitis (IgAV) or Henoch-Schönlein purpura (HSP) is one of the most common causes of systemic vasculitis in children. The long-term prognosis is dependent on renal involvement. IgAV with nephritis (IgAVN) occurs in about one third of IgAV patients [1]. The risk of progression to renal failure is estimated from 2% [2], to 20% in specialized centers [3]. Even if poor prognosis seems to be linked to severe initial clinical or histological presentation, a poor outcome may occur even in patients with isolated hematuria or mild proteinuria at disease onset [4,5]. Thus, the individual prognosis of IgAVN is difficult to establish and its management remains controversial.

The widely used International Study of Kidney Disease in Children (ISKDC) classification for IgAVN is mainly based on the presence of crescents and it does not completely correlate with the clinical presentation and long-term prognosis of IgAVN. This might explain partially why many authors did not identify histological markers as a prognostic factor [3, 6, 7].

We know that IgAVN and IgA Nephropathy (IgAN) have many similarities in terms of clinical presentation and pathophysiology [8]. The Oxford Classification assesses lesions depending on the presence of mesangial hypercellularity, glomerulosclerosis (GS), endocapillary proliferation (EP) or interstitial fibrosis and tubular atrophy (IF/TA). These histological characteristics are now recognized as prognostic factors in IgAN [9]. In 2014, a first evaluation of the Oxford Classification in IgAVN in adults showed that EP and IF/TA lesions were associated with long-term renal function impairment [10].

In view of these results, it seems interesting to analyse more histological parameters in IgAVN long-term prognosis. The aim of this study was to evaluate renal prognosis in children with IgAVN and to analyze the relation to clinical and histological prognostic factors at disease onset and the chosen treatment.

Method

We performed a retrospective multicenter study in the pediatric nephrology units of Armand Trousseau Hospital, Robert Debré Hospital and Necker Enfant Malades Hospital from 2000 to 2015.

Patients

All patients from 1 to 18 years at disease onset, with a clinical diagnosis of IgAV according to criteria defined by the American College of Rheumatology [11], with a diagnosis of IgAVN including renal biopsy with histological prove of predominant mesangial IgA immune deposits and with a minimal follow-up of six months were considered for inclusion.

All biopsy specimens were examined by light microscopy and immunofluorescence microscopy.

Histological parameters were extracted from the original histopathological report for each renal specimen.

Histological parameters were defined as follows:

‘MP or hypercellularity’ was defined as equal to or greater than four mesangial cells in any mesangial area and more than 50% of glomeruli with mesangial hypercellularity. The category ‘EP’ was defined by the presence of EP in at least one glomerulus. The category ‘GS’ was defined by the presence of GS in at least one glomerulus. The category ‘IF/TA’ was defined by more than 25% of cortical area affected by tubular atrophy and/or interstitial fibrosis. The category ‘cellular crescents’ was defined by the presence of at least one cellular crescent. The category ‘fibrous crescents’ was defined by the presence of at least one fibrous crescent.

Fibrous crescents, GS, IF/TA were reported and defined as chronic lesions. Cellular or fibro-cellular crescents, EP and inflammatory tubulointerstitial lesions were reported and defined as

acute lesions. Inflammatory tubulointerstitial lesions include interstitial mononuclear infiltrate, interstitial edema, and acute tubular damage.

Clinical and biological features

At the time of renal biopsy, clinical and biological data were evaluated: serum creatinine, total protein, albumin, and proteinuria were collected. Nephrotic syndrome (NS) was defined as albumin <25 g/L in association with nephrotic proteinuria (urine protein/creatinine ratio >250 mg/mmol or 24-h protein >50 mg/kg/24H). A nephrotic range proteinuria was defined as a proteinuria >250 mg/mmol without hypoalbuminemia and a significant proteinuria was defined by a proteinuria between 20 mg/mmol and 250 mg/mmol. Hypertension was defined as average systolic or diastolic blood pressure greater than or equal to the 95th percentile for age, gender, and height. The 2009 Schwartz formula was used to estimate glomerular filtration rate (eGFR) from the serum creatinine and height. Demographic characteristics collected from the medical history such as gender, age at onset, and age at biopsy were collected.

The onset of renal involvement in IgAV was defined as discovery of hematuria and/or proteinuria on dip stick.

Treatment

Treatment modalities were collected and summarized in six groups: no immunosuppressive treatment, oral corticosteroids alone, angiotensin-converting enzyme inhibitors and angiotensin receptor blockers (ACEi/ARBs) alone, oral corticosteroids and ACEi/ARBs, methylprednisolone pulse therapy followed by oral corticosteroids, or other immunosuppressive therapy.

Despite slight differences among the three centers, the basic modality for steroid pulses was 1 g/1.73 m² on day 1,3, and 5. Oral prednisone was given at a dosage of 2 mg/kg per day for 30 days, followed by a tapering down over the three following months with a cumulative prednisone dose of 3900 mg/m².

Monitoring and endpoint

Patients' data were recorded until their last documented outpatient visit.

The primary endpoint was IgAVN remission defined by negative proteinuria (< 20 mg/mmol of urinary creatinine) and a GFR >90 ml/min/1.73m² during the follow-up.

Statistical analysis

Quantitative variables are presented as median and interquartile and qualitative variables as percentages. Dichotomous variables were compared using the chi-squared test. For all continuous variables, if the Shapiro-Wilk test revealed a non-normal distribution, the Rank Sum Test was used, if the Shapiro-Wilk test revealed a normal distribution, student test were used. *p* value < 0.05 were considered significant.

Logistic regression models were used to study the association between the patient characteristics and outcome. For multivariate analysis, the primary endpoint was IgAVN remission one year after the diagnosis. We first performed univariable logistic regressions on all the patient characteristics to determine which ones to include in our final models. All variables with a P-value greater than 0.2 were included in the multivariable logistic regression models. All continuous variables were tested for linearity with the SAS macro LGTPHCURV9. All tests were performed at an α -risk value of 0.05. Statistical analysis was performed with SAS 9.2.

Results

Baseline patients' characteristics

A total of 159 patients with a diagnosis of IgAVN followed for a minimum of six months were included.

Among these 159 patients, there were 85 boys and 74 girls (sex ratio 0.88), the median age at the time of renal biopsy was 7.6 years (5.8-9.5). The median duration from the time of HSP diagnosis to renal involvement (discovery of hematuria and/or proteinuria on dip stick) was 17 days (6-32). 113 (71%) developed renal involvement within 30 days after the HSP onset, 36 (23%) between day 31 and day 180 and 2 (1%) between day 180 and the end of the first year. Eight patients developed a renal involvement more than one year after their first HSP clinical manifestation. The median duration from the renal involvement and the renal biopsy was 21 (10-39) days.

The median eGFR was 110 ml/min/1.73m² (87.9-130.4), 9 children (5%) had a GFR <60 ml/min/1.73m², 33 (21%) a GFR between 60 and 90 ml/min/1.73m² and 117 (74%) a GFR >90ml/min/1.73m².

The median initial proteinuria was 2820 mg/L (1440-5000), with a median proteinuria/creatininuria ratio of 330 mg/mmol (180-630) and median serum albumin of 32 g/L (27-37). At the time of the renal biopsy, 31 patients (19%) had a NS, 51 (32%) patients had a nephrotic range proteinuria and 77 (48%) patients had a significant proteinuria.

31 (19%) patient had a blood pressure above the 95th percentile at diagnosis. 128 (80%) patients had no high blood pressure.

histological patients' characteristics

Per kidney biopsy, a median number of 17 glomeruli could be assessed (IQR 13-24), 8 biopsies has less than 7 glomeruli and 8 biopsies had between 7 and 10 glomeruli.

Histological findings revealed mesangial IgA deposits in all patients. Glomerular crescents in 80 biopsies (50%), and 16 patients has more than 50% of glomeruli with crescents. Only 5 (3%) patients had fibrous crescents.

Mesangial proliferation was present on 129 biopsies (81%) and EP was present on 136 biopsies (86%). GS was present on 10 and IF/TA on 12 biopsies: in total, 19 patients had chronic lesions. 34 patients had interstitial mononuclear infiltrate, interstitial edema, and tubular damage.

Treatment

Oral steroid therapy was administered in 141 patients (88%) and a median dose of 3990 mg/m² (3990-4200). 31 (19%) patients received oral steroids alone and 81 patients received three methylprednisolone pulses followed by oral corticosteroids. 18 patients (11%) did not receive steroids. 14 patients received other immunosuppressive treatments including azathioprine and cyclophosphamide. Treatment with ACEi/ARBs was administered in 119 patients (75%) for a median of 445 days (157 to 1156). 9 (6%) patients received ACEi/ARBs alone and 110 (69%) patients received ACEi/ARBs and oral steroids.

These results are presented in Table 1.

Follow-up results

Patients were followed for a median time of 37.4 months (20-76). Overall, 112 patients (70%) were in remission after 175 days (97.5-335). At last follow up, the median eGFR was 110.5 mL/min/1.73m² (91.9-127.6), no patient had a GFR <60 ml/min/1.73m² except two patients with a renal transplantation.

47 (30 %) patients were not in remission. At the end of the follow-up, 19 patients (12%) of the cohort had an eGFR <90 ml/min/1.73m² and 79 (50%) patients had no assessment of renal

function. Nine patients had an eGFR <90 ml/min/1.73m² without proteinuria. Two patients had a kidney transplant, the first patient was 6 years old at diagnosis; he had a nephrotic syndrome with a renal failure (eGFR=37 ml/min/1.73m²) and on renal biopsy 70% of glomeruli with crescents without chronic lesions. The other one was 12 years old, with nephrotic proteinuria, without hypoalbuminemia and a mild renal failure (eGFR=77ml/min/1.73m²). He also had crescents in 30% of glomeruli

At last follow-up, among these 47 patients who were not in remission, the median eGFR was 89.1 mL/min/1.73m² (79.4-122.1) and the median proteinuria/creatininuria ratio was 40 mg/mmol (20-85).

Clinical and therapeutic prognosis factors

Patients in remission were significantly younger than patients not in remission 7.2 vs. 8.4 (p=0.003). Initial eGFR of patients not in remission was significantly lower than that of patients in remission (99.9 vs. 115; p=0.02) and patients not in remission received significantly more ACE inhibitors whether alone (91% vs. 68%; p=0.001) or in association with steroids (63% vs 82%; p=0.015) than patients in remission. The proportion of patients who received steroids alone was significantly higher in patients in remission than in patients not in remission (26% vs. 4%; p=0.002). There was no statistically significant difference between patients in remission and patients not in remission in terms of gender, duration between diagnosis of HSP and nephritis, duration between the diagnosis of nephritis and kidney biopsy, proteinuria and steroid treatment. These results are presented in Table 2.

Histological prognostic factors

There was no statistically difference in terms of presence of EP, cellular crescents or acute tubulointerstitial lesions between the patients in remission vs. patients not in remission. Patients in remission had significantly less GS (p=0.028), AT/FI (p=0.09) and chronic lesions

($p=0.01$) than patients not in remission in univariate analysis. These results are presented in Table 3.

Patients with chronic lesions have a significant longer delay between IgAVN diagnosis and biopsy than patients without chronic lesions, (48 vs. 21 days; $p=0.046$). The delay between IgAVN diagnosis and biopsy for each patient is shown in Figure 1. There was no difference in terms of age, delay between HSP diagnosis and renal involvement, eGFR, proteinuria, and treatment between patients with chronic lesions and patients without chronic lesions. These results are shown in Table 4.

In univariate analysis, there was no difference in terms of crescents and EP between the two groups ($p=0.71$ and $p=0.46$ respectively). The level of initial proteinuria was similar in the two groups ($p=0.56$). The delay between renal involvement and biopsy and the proportion of chronic lesions were significantly higher in patients not remission ($p=0.03$ and $p=0.005$ respectively).

In multivariate analysis, chronic lesions were significantly associated with the absence of remission one year after IgAVN diagnosis: odds ratio: 3,84 with 95% confidence interval (1.118-12.445). These results are shown in Table 5.

Discussion

In this retrospective study, we analysed renal prognosis in children with kidney biopsies for IgAVN since 2000. Overall 112 patients out of 159 were in remission at the end of a follow-up of 37 months. This show, that almost one third of pediatric patients presented a chronic renal disease 3 years after IgAVN onset. This result is similar to historical series: in 1992, Goldstein *et al* reported persistent kidney disease in 35% of 78 patients [12] after a follow-up of 23.4 years and in 1997 Coppo *et al* reported an absence of remission in 30% of patients after 4.8 years [6]. More recent studies have also found the same proportion of persistent

kidney disease: in 2005, among 78 patients included in the study of Halling *et al*, 26% had persistent renal disease after 5.2 years [13] and in 2007, Mir *et al* found 77% of favorable outcome among 141 children after 8.9 years [14]. IgAVN is generally recognized as an acute disease with a good prognosis, but a large proportion of children was still proteinuric three years after initial diagnosis. Considering that proteinuria is due to hyperfiltration lesions secondary to nephron loss, we can suppose that the proportion of patients with proteinuria may still increase in adulthood.

Our median number of glomeruli was 17; only 15 biopsies out of 159 had a number of glomeruli under 10, which is similar to what has been reported in the Oxford classification report [15]. We can consider that these kidney samples were sufficient for histological analysis.

Acute histological lesions like EP, mesangial proliferation, acute tubulointerstitial lesions, and cellular crescents were represented in a great proportion of our analysed biopsies. On the other hand, chronic lesions such as GS, IF/TA or fibrous crescents were very rare in our sample.

Nevertheless, the presence of chronic lesions was associated to the probability of persistent renal disease in multivariate analysis. The link between chronic lesions at diagnosis and persistent proteinuria during follow-up is not surprising and has been found in another previous study. These lesions should be evaluated in IgAVN histological analysis and should not be ignored in IgAVN histological classification. Therefore, we included in our histological classification all types of chronic lesions such as IF/TA, fibrous crescents, and GS, which are not part of ISKDC classification.

However, it is not clear in which circumstances this kind of lesions appear.

In our study, like in another German study concerning IgAVN histological features [16], a longer delay between nephritis and kidney biopsy was related with a higher proportion of

chronic lesions. Not surprisingly, longer delay after initial inflammation produces more sclerosis or fibrosis. Therefore, these results are very important for the clinician: following KDIGO guidelines, in patients with persistent proteinuria without renal failure (which is a large proportion of patients with IgAVN) no steroid treatment is recommended, which increases the risk to transform acute lesions into chronic lesions [17]. Furthermore, it has been shown that chronic lesions are insensitive to immunosuppressive therapy [18]. Therefore, it may be dangerous to delay steroid treatment in these patients as suggested in a recent review paper commenting these guidelines [19].

Another possible explanation for a high proportion of chronic lesions is patient age. Indeed, adult IgAVN patients have a higher proportion of chronic histological lesions: recently Kim *et al* studied 61 biopsy-proven patients with IgAVN. About one third of their patients had chronic lesions while only 15% of them had EP [20] and Inagaki *et al* studied the biopsy of 74 patients with IgAVN: GS was present in 50% of patients [21]. Even in children, the difference of histological features depending on patient age was highlighted: These authors found that younger patients had less often GS or chronic lesions on their initial biopsy [16]. The higher proportion of chronic lesions in older patients was also found in a study of IgAN in children [22].

This relation was not found in our study. However, older patients had a poorer prognosis than younger patients. Older patients seem to be closer to patients with IgAN and this may explain their poorer prognosis.

To summarize, the older the patient and the longer the interval to biopsy after initial nephritis, the more chronic lesions are found, which is associated to poor prognosis.

However, focusing on patients with chronic lesions, 40% had their biopsy done after less than 1 month and 25% even within less than 10 days after nephritis onset (Figure 2). This suggests

that a short delay to biopsy does not necessarily prevent chronic lesions in all patients because they are present since disease onset.

This particular group of patients with chronic lesions had a worse prognosis despite an early biopsy. Therefore, if the delay after initial nephritis is similar, the nature of the disease in these particular patients may be different. These patients, with “cold” histological parameters seem to be closer to IgAN. Indeed, in an analyses of 265 cases, a working group of the International IgA Nephropathy Network and the Renal Pathology Society found GS in more than 75% and IF/TA in more than 85% of patients and conversely EP in only 40% of patients [15].

In our study, EP was not associated to poor prognosis. EP was detected in 90% of patients, which could explain the difficulty to correlate EP with renal prognosis. A better quantification of EP might have improved the interpretation of this parameter. For example, no difference is made between segmental EP and diffuse EP. Like in many other studies [6,7,23], the presence of crescents was not associated to poor prognosis. The relatively short follow-up period could explain this result. Indeed, cellular crescents become fibrous crescents and provoke hyperfiltration lesions via nephron loss. These hyperfiltration lesions may have biological consequences (in terms of increased serum creatinine) only after a couple a years. This is particularly true in children as their functional reserve is higher than in adults.

This result can also illustrate the positive impact of steroid treatment, as the most severe histological forms are often treated more aggressively and those pathological findings (EP and crescents) would be improved by the appropriate therapy.

A great proportion of patients received steroids at IgAVN onset (88%) and this proportion was similar between patients with good or poor outcome. However, only 10% of patients did not receive steroid treatment and these patients probably had a mild clinical and histological presentation. This could explain the difficulty to analyse the positive steroid effect on renal

outcome in a retrospective study. Generally, steroid efficiency is difficult to highlight in IgAVN and meta-analysis are still not in favour of their use [1]. However, we showed in our study that a majority of clinicians use steroids in any type of initial clinical or histological presentation. Median cumulative steroid dose is rather high in our study (3990 mg/m²). The question of steroid efficiency in IgAVN needs to be clarified, because even such a high dosage was not able to prevent persistent renal disease in 30% of patients.

In our study, the use of ACEi/ARBs alone or in association with steroids was higher in patients not in remission. This was probably due to an indication bias of ACEi/ARBs. Those patients who had a persistent proteinuria after steroids therapy received ACEi/ARBs in order to decrease the persistent proteinuria. Thus, the most severe patients were treated with ACEi/ARBs.

Proteinuria at baseline was not correlated to renal prognosis in our study. A lot of other studies did not identify any link between initial proteinuria and renal prognosis [6,13,24]. Therefore, it seems that correlation between histological and biological parameters at IgAVN baseline rather bad. Indeed, patients without crescents have a very heterogeneous clinical presentation as previously reported [25,26]. This lack of correlation between initial proteinuria and histological lesions could explain the difficulty to identify proteinuria as an IgAVN prognostic factor. Another explanation is that patients with a higher proteinuria were probably more often treated with corticosteroids, which may explain their better prognosis due to a more aggressive treatment.

In our study, age at onset was associated with poor prognosis in univariate analysis. This result has been found in several studies [13,26,27]. Initial eGFR was different between patients with good prognosis and those with persistent proteinuria. However, initial eGFR was in the normal range in both groups, so that the difference seems to be difficult to interpret.

There are some limitations in our study: It was a retrospective study and patients enrolled had a different treatment. The follow up can be considered as too short to precisely highlight persistent chronic disease related to hyperfiltration lesions. The histopathological evaluation of the biopsy report was not standardized and histological parameters were not read by one pathologist.

In conclusion, 30% of children with IgAVN presented a persistent renal disease at the end of a 3-year follow-up. Chronic histological lesions, which may be present at disease onset, but not EP or crescents are associated with a bad prognosis and should be evaluated in IgAVN histological classification. Crescents were not associated with poor outcome, presumably due to more aggressive treatment and its efficiency. The subset of patients which presents with histological features of chronic disease at disease onset seems to have a clinical course closer to IgAN.

References

1. Chartapisak W, Opastirakul S, Hodson EM, Willis NS, Craig JC (2009) Interventions for preventing and treating kidney disease in Henoch-Schönlein Purpura (HSP). In: The Cochrane Collaboration (ed) Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, Chichester, UK
2. Stewart M, Savage JM, Bell B, McCord B (1988) Long term renal prognosis of Henoch-Schönlein purpura in an unselected childhood population. *Eur J Pediatr* 147:113–115
3. Ronkainen J, Ala-Houhala M, Huttunen NP, Jahnukainen T, Koskimies O, Ormälä T, Nuutinen M (2003) Outcome of Henoch-Schoenlein nephritis with nephrotic-range proteinuria. *Clin Nephrol* 60:80–84
4. Goldstein AR, White RH, Akuse R, Chantler C (1992) Long-term follow-up of childhood Henoch-Schönlein nephritis. *Lancet Lond Engl* 339:280–282
5. Tudorache E, Azema C, Hogan J, Wannous H, Aoun B, Decramer S, Deschênes G, Ulinski T (2015) Even mild cases of paediatric Henoch-Schönlein purpura nephritis show significant long-term proteinuria. *Acta Paediatr Oslo Nor* 104:843–848. <https://doi.org/10.1111/apa.12723>

6. Coppo R, Mazzucco G, Cagnoli L, Lupo A, Schena FP (1997) Long-term prognosis of Henoch-Schönlein nephritis in adults and children. Italian Group of Renal Immunopathology Collaborative Study on Henoch-Schönlein purpura. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc* 12:2277–2283
7. Soylemezoglu O, Ozkaya O, Ozen S, Bakkaloglu A, Dusunsel R, Peru H, Cetinyurek A, Yildiz N, Donmez O, Buyan N, Mir S, Arisoy N, Gur-Guven A, Alpay H, Ekim M, Aksu N, Soylu A, Gok F, Poyrazoglu H, Sonmez F, Turkish Pediatric Vasculitis Study Group (2009) Henoch-Schönlein nephritis: a nationwide study. *Nephron Clin Pract* 112:c199-204. <https://doi.org/10.1159/000218109>
8. Davin JC, Weening JJ (2001) Henoch-Schönlein purpura nephritis: an update. *Eur J Pediatr* 160:689–695
9. A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts ISD, Troyanov S, Alpers CE, Amore A, Barratt J, Berthouix F, Bonsib S, Bruijn JA, D'Agati V, D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene H-J, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li L-S, Li PKT, Liu Z-H, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. *Kidney Int* 76:534–545. <https://doi.org/10.1038/ki.2009.243>
10. Kim CH, Lim BJ, Bae YS, Kwon YE, Kim YL, Nam KH, Park KS, An SY, Koo HM, Doh FM, Lee MJ, Oh HJ, Yoo T-H, Kang S-W, Choi KH, Jeong HJ, Han SH (2014) Using the Oxford classification of IgA nephropathy to predict long-term outcomes of Henoch-Schönlein purpura nephritis in adults. *Mod Pathol Off J U S Can Acad Pathol Inc* 27:972–982. <https://doi.org/10.1038/modpathol.2013.222>
11. Goldstein AR, White RH, Akuse R, Chantler C (2010) EULAR/PRINTO/PRES criteria for Henoch-Schönlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara 2008. Part II: Final classification criteria. *Ann Rheum Dis* 69:798–806. <https://doi.org/10.1136/ard.2009.116657>
12. Goldstein AR, White RH, Akuse R, Chantler C (1992) Long-term follow-up of childhood Henoch-Schönlein nephritis. *Lancet Lond Engl* 339:280–282
13. Edström Halling S, Söderberg MP, Berg UB (2010) Predictors of outcome in Henoch-Schönlein nephritis. *Pediatr Nephrol Berl Ger* 25:1101–1108. <https://doi.org/10.1007/s00467-010-1444-y>
14. Mir S, Yavascan O, Mutlubas F, Yeniay B, Sonmez F (2007) Clinical outcome in children with Henoch-Schönlein nephritis. *Pediatr Nephrol Berl Ger* 22:64–70. <https://doi.org/10.1007/s00467-006-0278-0>
15. A Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, Cattran DC, Coppo R, Cook HT, Feehally J, Roberts ISD, Troyanov S, Alpers CE, Amore A, Barratt J, Berthouix F, Bonsib S, Bruijn JA, D'Agati V,

- D'Amico G, Emancipator S, Emma F, Ferrario F, Fervenza FC, Florquin S, Fogo A, Geddes CC, Groene H-J, Haas M, Herzenberg AM, Hill PA, Hogg RJ, Hsu SI, Jennette JC, Joh K, Julian BA, Kawamura T, Lai FM, Leung CB, Li L-S, Li PKT, Liu Z-H, Mackinnon B, Mezzano S, Schena FP, Tomino Y, Walker PD, Wang H, Weening JJ, Yoshikawa N, Zhang H (2009) The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. *Kidney Int* 76:534–545. <https://doi.org/10.1038/ki.2009.243>
16. Hennies I, Gimpel C, Gellermann J, Möller K, Mayer B, Dittrich K, Büscher AK, Hansen M, Aulbert W, Wühl E, Nissel R, Schalk G, Weber LT, Pohl M, Wygoda S, Beetz R, Klaus G, Fehrenbach H, König S, Staude H, Beringer O, Bald M, Walden U, von Schnakenburg C, Bertram G, Wallot M, Häffner K, Wiech T, Hoyer PF, Pohl M, German Society of Pediatric Nephrology (2018) Presentation of pediatric Henoch-Schönlein purpura nephritis changes with age and renal histology depends on biopsy timing. *Pediatr Nephrol Berl Ger* 33:277–286. <https://doi.org/10.1007/s00467-017-3794-1>
 17. (2012) Chapter 11: Henoch-Schönlein purpura nephritis. *Kidney Int Suppl* 2:218–220. <https://doi.org/10.1038/kisup.2012.24>
 18. Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. *Pediatr Nephrol Berl Ger* 12:238–243
 19. Davin J-C, Coppo R (2013) Pitfalls in recommending evidence-based guidelines for a protean disease like Henoch-Schönlein purpura nephritis. *Pediatr Nephrol* 28:1897–1903. <https://doi.org/10.1007/s00467-013-2550-4>
 20. Kim CH, Lim BJ, Bae YS, Kwon YE, Kim YL, Nam KH, Park KS, An SY, Koo HM, Doh FM, Lee MJ, Oh HJ, Yoo T-H, Kang S-W, Choi KH, Jeong HJ, Han SH (2014) Using the Oxford classification of IgA nephropathy to predict long-term outcomes of Henoch-Schönlein purpura nephritis in adults. *Mod Pathol Off J U S Can Acad Pathol Inc* 27:972–982. <https://doi.org/10.1038/modpathol.2013.222>
 21. Inagaki K, Kaihan AB, Hachiya A, Ozeki T, Ando M, Kato S, Yasuda Y, Maruyama S (2018) Clinical impact of endocapillary proliferation according to the Oxford classification among adults with Henoch-Schönlein purpura nephritis: a multicenter retrospective cohort study. *BMC Nephrol* 19:208. <https://doi.org/10.1186/s12882-018-1009-z>
 22. Shima Y, Nakanishi K, Hama T, Mukaiyama H, Togawa H, Hashimura Y, Kaito H, Sako M, Iijima K, Yoshikawa N (2012) Validity of the Oxford classification of IgA nephropathy in children. *Pediatr Nephrol Berl Ger* 27:783–792. <https://doi.org/10.1007/s00467-011-2061-0>
 23. Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study. *Lancet Lond Engl* 360:666–670. [https://doi.org/10.1016/S0140-6736\(02\)09835-5](https://doi.org/10.1016/S0140-6736(02)09835-5)
 24. Butani L, Morgenstern BZ (2007) Long-term outcome in children after Henoch-Schönlein purpura nephritis. *Clin Pediatr (Phila)* 46:505–511. <https://doi.org/10.1177/0009922806298896>

25. Halling SFE, Söderberg MP, Berg UB (2005) Henoch Schönlein nephritis: clinical findings related to renal function and morphology. *Pediatr Nephrol Berl Ger* 20:46–51. <https://doi.org/10.1007/s00467-004-1650-6>
26. Delbet JD, Hogan J, Aoun B, Stoica I, Salomon R, Decramer S, Brocheriou I, Deschênes G, Ulinski T (2017) Clinical outcomes in children with Henoch-Schönlein purpura nephritis without crescents. *Pediatr Nephrol Berl Ger* 32:1193–1199. <https://doi.org/10.1007/s00467-017-3604-9>
27. Coppo R, Andrulli S, Amore A, Gianoglio B, Conti G, Peruzzi L, Locatelli F, Cagnoli L (2006) Predictors of outcome in Henoch-Schönlein nephritis in children and adults. *Am J Kidney Dis Off J Natl Kidney Found* 47:993–1003. <https://doi.org/10.1053/j.ajkd.2006.02.178>

Figure 1. histological lesions depending on delay between HSPN and biopsy

Table 1

Patients n=159	
Baseline characteristics	
Girls n (%)	74 (47%)
Boys n (%)	85 (53%)
Age at onset on HSPN year (QI-QS)	7.6 years (5.8-9.5).
Duration HSP → RI day (QI-QS)	17 days (6-32).
Duration HSPN → biopsy day (QI-QS)	21 (10-39)
GFR ml/min/1.73m ² (QI-QS)	110 (87.9-130.4)
Proteinuria mg/L (QI-QS)	2820 (1440-5000)
Protéinuria/créatininuria mg/mmol (QI-QS)	330 (180-630)
Albumin g/l (QI-QS)	32 g/L (27-37).
Nephrotic syndrome	31 (19%)
HTA	31 (19%)
Treatment	
Oral corticosteroids, n (%)	141 (88%)
Methylprednisolone pulse, n (%)	81 (51%)
No corticosteroids, n (%)	18 (11%)
ACEi/ARBs, n (%)	119 (75%)
ACEi/ARBs alone, n (%)	9 (6%)
Oral corticosteroids alone, n (%)	31 (19%)
Oral corticosteroids + ACEi/ARBs, n (%)	110 (69%)
Another immunosuppressive agent, n (%)	14 (9%)
Histological characteristics	
Glomeruli (QI-QS)	17 (13-24)
Mesangial proliferation n (%)	129 (81%)
Endocapillary proliferation n (%)	136 (86%)
Cellular crescents n (%)	78 (49%)
Acute tubulointerstitial lesions n (%)	34 (21%)
Fibrous crescents n (%)	6 (4%)
Glomerular sclerosis n (%)	10 (6%)
IF/TA n (%)	12 (7%)
Chronic lesions n (%)	19 (12%)

Table 1: Baseline characteristics of the population.

QI = lower quartile (25th percentile)

QS = upper quartile (75th percentile)

RI = renal involvement

IF/TA = interstitial fibrosis and tubular atrophy

	Remission	No remission	
Risk factors	<i>n</i> = 112	<i>n</i> = 47	<i>p</i>
Gender girl/boy	54/58	20/27	0.516
Age years (<i>QI-QS</i>)	7.2 (5,6-8,8)	8.4 (6.5-12.2)	0.003
GFR ml/min/1.73m ² (<i>QI-QS</i>)	115 (94.64-138.3)	99.9 (79.1-112.9)	0.02
Duration HSP → RI day (<i>QI-QS</i>)	16.5 (6-31.7)	17 (8-33)	0.64
Duration HSPN → biopsy day (<i>QI-QS</i>)	20.5 (10-38)	22.5 (9.5-55)	0.35
Duration follow-up months (<i>QI-QS</i>)	35.6 (20- 58.5)	52.6 (18.2-93.7)	0.053
Proteinuria mg/mmol (<i>QI-QS</i>)	367.5 (182.5-615.75)	300 (180-637)	0.46
Treatment			
Oral corticosteroids <i>n</i> (%)	100/112 (89%)	41/47 (87%)	0.6
Methylprednisolone pulse <i>n</i> (%)	57/112 (50%)	24/47 (51%)	0.98
ACEi/ARBs <i>n</i> (%)	76/112 (68%)	43/47 (91%)	0.001
Oral corticosteroids alone <i>n</i> (%)	29/112 (26%)	2/47 (4%)	0.002
Oral corticosteroids and ACEi/ARBs <i>n</i> (%)	71/112 (63%)	39/47 (82%)	0.015
ACEi/ARBs alone <i>n</i> (%)	5/112 (4%)	5/47 (10%)	0.146

Table 2. Analysis of clinical risk factors and treatment associated to the remission

RI = renal involvement

HSP = Henoch schonlein purpura

HSPN = Henoch schonlein purpura nephritis

	Remission	No remission	
Risk factors	<i>n</i> = 112	<i>n</i> = 47	<i>p</i>
Endocapillary proliferation	93/112 (83%)	43/48 (89%)	0.17
Cellular crescents	54/112 (48%)	26/47 (55%)	0.41
Acute tubulointerstitial lesions	21/112 (18%)	13/47 (27%)	0.189
Glomerular sclerosis	4/112(4%)	6/47 (13%)	0.028
IF/TA	4/112 (4%)	8/47 (17%)	0.009
Chronic lesions	7/112 (6%)	12/47 (26%)	0.001

Table 3. Analysis of histological risk factors associated to the remission

IF/TA = interstitial fibrosis and tubular atrophy

	Chronic lesions	Acute lesions	
Risk factors	n= 19	n= 140	p
Duration HSPN → biopsy day (QI-QS)	48 (10-109)	21 (10-37)	0.046
Age year (QI-QS)	7.5 (5.7-11.1)	7.6 (5.8-9.5)	0.63
Duration HSP → RI day (QI-QS)	28 (5-91)	16 (6,25-30,7)	0.185
GFR ml/min/1,73m2 (QI-QS)	102,5 (80-119)	113 (89-133)	0.19
Proteinuria mg/mmol (QI-QS)	280 (120-730)	340 (192-620)	0.37
Oral corticosteroids n (%)	17 (89%)	124 (88%)	0.97

Table 4. Analysis of clinical risk factors associated to the presence of chronic lesions

RI = renal involvement

HSP = Henoch schonlein purpura

HSPN = Henoch schonlein purpura nephritis

	Remission	No remission	Univariate analysis	Multivariate analysis
Risk factors	n= 95	n= 40	p	OR 95% CI
Age year (QI-QS)	8 (6.4-9.5)	8.5 (6.5-12.3)	0.002	0.82 (0.72-0.95)
Cellular crescents n (%)	49 (51%)	22 (55%)	0.71	
Endocapillary proliferation n (%)	81 (85%)	36 (90%)	0.46	
Proteinuria mg/mmol (QI-QS)	357(180-630)	275 (147-564)	0.56	1.0 (0.99-1.001)
duration HSPN → biopsy day (QI-QS)	19 (9-38)	31(10-64)	0.03	0.99 (0.99-1.002)
Chronic lesions n (%)	7 (7.3%)	10 (25%)	0.005	3.84 (1.18-12.44)

Table 5 Analysis of risk factors associated to the remission one year after IgAVN diagnosis

HSPN = Henoch schonlein purpura nephritis